Privacy voorkeur

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


ISTH News | thrombosis: new developments

Round Table number 3 from the ISTH in Kyoto focuses on the status quo of the new oral anti-coagulants for the treatment of venous thromboembolism and prevention of recurrence as wel as for stroke prevention in patients with atrial fibrillation. Professor Gregory Lip and dr Menno Huisman summarize the current clinical data for the new oral anticoagulants for these indications and discuss the impact and challenges for daily clinical practice. Moderator of the Round Table is dr Evert-Jan de Kruijf, hematologist from the Netherlands.

  • This program is editorially independent and is financially made possible by

Related items

Quarterly focus

September 25th: Quarterly Focus: highlights in Hodgkin Lymphoma

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Hematology has developed a program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. On September 25th, two high-impact international publications on Hodgkin Lymphoma of the past year will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. During this live broadcast you will have the unique opportunity to interact with our expert panel and the authors and ask them your questions. The expert panel consists of: Josée Zijlstra, MD, PhD, hematologist, VUmc Amsterdam Wouter Plattel, MD, PhD, hematologist, UMC Groningen Live video guests: HD18: Prof. Peter Borchmann, MD, PhD, hematologist, University Hospital of Cologne, Germany H10: Prof. Massimo Federico, MD, PhD, medical oncologist, University of Modena and Reggio Emilia, Italy

Congress news

EHA 2014 News Report 3

In the third EHA News Report, Prof. Anna Falanga highlights the three presentations held at the Education Session on Thrombosis, Prof. Richard Schlenk reviews a selection of presentations regarding AML and Prof. Andreas Hochhaus discusses the highlights of the EHA congress on CML.

Congress news

ASH 2013 Prevention and Management of VT Disease

In the third magazine from the ASH in New Orleans, you will be updated on Prevention and Management of Venous Throboembolic Disease Prevention of Venous Thromboembolism after Orthopedic Surgery (Alejandro Lazo-Langner) Predictors of Venous Thromboembolism Recurrence (John Heit) Prevention Of Venous Thromboembolism in Elective Total Hip Replacement (Stephanie Young)

Congress news

ASH 2013 Trials and Cohort studies

In the second magazine from the ASH in New Orleans, you will be updated on trials and cohort studies. The Sox Trial: Predictors of the Post-Thrombotic Syndrome (Dr. Susan Kahn) Quality of VKA therapy after extreme overanticoagulation (Dr. Hilde Kooistra) Q-VTE Study Cohort: Oral anticoagulation after venous thromboembolism (Dr. Vicky Tagalakis)

Congress news

ASH 2013 Anticoagulant and antithrombotic therapy

In the first magazine from the ASH in New Orleans, you will be updated on anticoagulant and antithrombotic therapy. Real Life Efficacy and Safety Of Rivaroxaban For Stroke Prevention in AF (Dr. Jan Beyer-Westendorf), Comparison of anticoagulant agents in Venous Thromboembolic Disease (dr. Simon Mantha), Major Bleeding and Reversal therapy in Vitamin K Antagonist therapy (Dr. Nakisa Khorsand)

Congress news

ASH 2012 | Hematology News Program 3

Third Hematology TV News Program from the ASH 2012 TPA-agonist romiplostim: can we reconsider its use in MDS? Have we arrived into the era of targeted therapy in CLL with ibrutinib? JAK-inhibition may be relevant for MPN beyond myelofibrosis